The Discounted Cash Flow (DCF) valuation of Xvivo Perfusion AB (XVIVO.ST) is (140.97) SEK. With the latest stock price at 458.50 SEK, the upside of Xvivo Perfusion AB based on DCF is -130.7%.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| WACC / Discount Rate | 5.5% - 8.7% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (989.64) - (73.07) | (140.97) |
| Upside | -315.8% - -115.9% | -130.7% |